Research presented at the 2017 European Cancer Congress describes the potential of a noninvasive diagnostic test for esophageal and gastric cancers that measures chemicals in the breath.
Measurements of copies of a single gene circulating in the bloodstream allowed scientists to identify patients with stomach cancer who were most likely to respond to treatment.
The heliobacter pylori bacterium is the main cause of stomach ulcers, and it also a known risk factor for non-cardia gastric cancer.
Researchers found that the vagal nerve contributes to the growth of gastric tumors through the release of a neurotransmitter.
In a massive effort to catalog the molecular causes of stomach cancer, scientists have identified four subtypes of tumors based on shared mutations and other molecular abnormalities. They say the new classification promises to advance clinical research to develop improved therapies for the third-leading cancer killer worldwide.
Cyramza (ramucirumab) has been approved by the U.S. Food and Drug Administration to treat cancer of the stomach.
Stomach and bowel cancer—two of the most common cancers worldwide—could be treated with a class of medicines that are currently used to treat a blood disorder, according to new research.
This fact sheet reviews common sites of cancer metastasis, methods of spread, treatment, and additional details.
Survivors of Hodgkin lymphoma who received subdiaphragmatic radiotherapy had dose-dependent increased risk for stomach cancer, researchers discovered.
Stomach cancer, one of the leading causes of cancer death worldwide, actually falls into three broad subtypes that respond differently to currently available therapies, according to new research.
Non-Hodgkin lymphoma rates down but carcinoma rates fairly constant from 1980 to 2007.
Mutations were seen in FAT4 and ARID1A, involved in cell adhesion and chromatin remodeling.
With the exception of lung cancer in women and pancreatic cancer, mortality from major cancers is expected to decline in the European Union in 2012.
A large study showed that people with AIDS are 6.9-fold more likely than the general population to develop stomach malignancies and 2.7 times more likely to have esophageal malignancies.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|